You have read all your free articles, to continue reading subscribe to read the rest of this content.
AstraZeneca’s Forxiga (dapagliflozin) has been recommended for an indication extension of its marketing authorisation in the European Union (EU) for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF) in adults with and without type-2 diabetes (T2D). The Already a subscriber Login You have read all your free articles,…
The company has presented one-year data on survival rate, immune activation and safety in the modified cohort of the TG01 trial in resected pancreatic cancer patients. The trial is an open label, phase I/II trial of TG01/GM-CSF in combination with gemcitabine as adjuvant therapy for treating patiAlready a subscriber Login…
The European Medicines Agency (EMA) has accepted the company’s Marketing Authorization Application (MAA) for review of IDEFIRIX (INN: imlifidase). Hansa Biopharma is seeking approval of IDEFIRIX as a treatment to enable kidney transplantation in highly sensitized patients. IDEFIRIX is a novel aAlready a subscriber Login You have read all your…
AstraZeneca has agreed to sell the rights to Crestor (rosuvastatin) and associated medicines in over 30 countries in Europe, except the UK and Spain, to Grünenthal. Crestor is a statin approved for the treatment of dyslipidaemia and hypercholesterolaemia. "This agreement supports the managemeAlready a subscriber Login You have read all…
